A Multi-center, Double-blind, Placebo-controlled Phase II Study of the Efficacy and Safety of Canakinumab in Subjects With Schnitzler Syndrome

Trial Profile

A Multi-center, Double-blind, Placebo-controlled Phase II Study of the Efficacy and Safety of Canakinumab in Subjects With Schnitzler Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Schnitzler syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2016 New trial record
    • 19 Sep 2016 Results of 16 week study assessing efficacy and safety,published in the Journal of Allergy and Clinical Immunology (2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top